UBS analyst Kevin Caliendo raised the firm’s price target on Alignment Healthcare (ALHC) to $17 from $16 and keeps a Neutral rating on the shares. Alignment Healthcare posted a “strong” Q1, with beats across the board, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare Reports Strong Q1 2025 Results
- Alignment Healthcare’s Strong Q1 2025 Performance and Positive Outlook Justify Buy Rating
- Alignment Healthcare sees Q2 revenue $950M-$965M, consensus $945.89M
- Alignment Healthcare raises FY25 revenue view to $3.77B-$3.82B from $3.72B-$3.78
- Alignment Healthcare CFO Thomas Freeman to step down, Jim Head to succeed